EGTX.ST Stock Analysis
EG
Uncovered
Egetis Therapeutics AB (publ) is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Egetis Therapeutics AB is a pharmaceutical drug development company, which engages in the development of new drugs for treatment of life threatening diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.